Cargando…

Effect of visual impairment on depression and anxiety during the COVID-19 pandemic in the United States

OBJECTIVE: To evaluate associations between visual impairment, anxiety, and depression during the COVID-19 pandemic in the United States. DESIGN: Retrospective cross-sectional design. METHODS: This study included a cohort of U.S. adults enrolled in the National Institutes of Health All of Us Researc...

Descripción completa

Detalles Bibliográficos
Autores principales: Sekimitsu, Sayuri, Shweikh, Yusrah, Zebardast, Nazlee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Canadian Ophthalmological Society. Published by Elsevier Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712066/
https://www.ncbi.nlm.nih.gov/pubmed/36529268
http://dx.doi.org/10.1016/j.jcjo.2022.11.019
_version_ 1784841717024817152
author Sekimitsu, Sayuri
Shweikh, Yusrah
Zebardast, Nazlee
author_facet Sekimitsu, Sayuri
Shweikh, Yusrah
Zebardast, Nazlee
author_sort Sekimitsu, Sayuri
collection PubMed
description OBJECTIVE: To evaluate associations between visual impairment, anxiety, and depression during the COVID-19 pandemic in the United States. DESIGN: Retrospective cross-sectional design. METHODS: This study included a cohort of U.S. adults enrolled in the National Institutes of Health All of Us Research Program. Individuals who were blind/visually impaired (BVI) were identified via Systematized Nomenclature of Medicine (SNOMED) codes and compared with a control cohort. Prevalences of baseline, new, and worsened depression and anxiety, as defined by SNOMED codes and medication use, were compared between the 2 groups. Anxiety and depression during the COVID-19 pandemic were evaluated using the Generalized Anxiety Disorder 7 and the Patient Health Questionnaire 9 surveys, respectively. RESULTS: A total of 324,915 participants (7526 BVI individuals and 317,389 control individuals) were included. BVI individuals had higher prevalences of baseline anxiety and depression (50.4% vs 28.7%; p < 0.001), new anxiety and depression (0.98% vs 0.66%; p < 0.001), and worsened anxiety and depression throughout the COVID-19 pandemic (0.19% vs 0.07%; p < 0.001) compared with control individuals. Being BVI was significantly associated with baseline and worsened anxiety and depression after controlling for age, sex, race, ethnicity, and comorbidity (adjusted odds ratio [aOR] = 1.61; 95% CI, 1.46–1.78 and aOR = 2.07; 95% CI, 1.03–4.13). Similarly, being BVI was associated with a 2.07 point increase on the Generalized Anxiety Disorder 7 survey (adjusted β = 2.07; 95% CI, 1.32–3.27) and a 2.96 point increase on the Patient Health Questionnaire 9 survey (adjusted β = 2.96; 95% CI, 1.64–5.36). CONCLUSIONS: These findings indicate that BVI individuals were disproportionately affected by anxiety and depression at baseline and throughout the pandemic, highlighting an important need to promote access to mental health services among this population.
format Online
Article
Text
id pubmed-9712066
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Canadian Ophthalmological Society. Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-97120662022-12-01 Effect of visual impairment on depression and anxiety during the COVID-19 pandemic in the United States Sekimitsu, Sayuri Shweikh, Yusrah Zebardast, Nazlee Can J Ophthalmol Original Article OBJECTIVE: To evaluate associations between visual impairment, anxiety, and depression during the COVID-19 pandemic in the United States. DESIGN: Retrospective cross-sectional design. METHODS: This study included a cohort of U.S. adults enrolled in the National Institutes of Health All of Us Research Program. Individuals who were blind/visually impaired (BVI) were identified via Systematized Nomenclature of Medicine (SNOMED) codes and compared with a control cohort. Prevalences of baseline, new, and worsened depression and anxiety, as defined by SNOMED codes and medication use, were compared between the 2 groups. Anxiety and depression during the COVID-19 pandemic were evaluated using the Generalized Anxiety Disorder 7 and the Patient Health Questionnaire 9 surveys, respectively. RESULTS: A total of 324,915 participants (7526 BVI individuals and 317,389 control individuals) were included. BVI individuals had higher prevalences of baseline anxiety and depression (50.4% vs 28.7%; p < 0.001), new anxiety and depression (0.98% vs 0.66%; p < 0.001), and worsened anxiety and depression throughout the COVID-19 pandemic (0.19% vs 0.07%; p < 0.001) compared with control individuals. Being BVI was significantly associated with baseline and worsened anxiety and depression after controlling for age, sex, race, ethnicity, and comorbidity (adjusted odds ratio [aOR] = 1.61; 95% CI, 1.46–1.78 and aOR = 2.07; 95% CI, 1.03–4.13). Similarly, being BVI was associated with a 2.07 point increase on the Generalized Anxiety Disorder 7 survey (adjusted β = 2.07; 95% CI, 1.32–3.27) and a 2.96 point increase on the Patient Health Questionnaire 9 survey (adjusted β = 2.96; 95% CI, 1.64–5.36). CONCLUSIONS: These findings indicate that BVI individuals were disproportionately affected by anxiety and depression at baseline and throughout the pandemic, highlighting an important need to promote access to mental health services among this population. Canadian Ophthalmological Society. Published by Elsevier Inc. 2022-12-01 /pmc/articles/PMC9712066/ /pubmed/36529268 http://dx.doi.org/10.1016/j.jcjo.2022.11.019 Text en © 2022 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Sekimitsu, Sayuri
Shweikh, Yusrah
Zebardast, Nazlee
Effect of visual impairment on depression and anxiety during the COVID-19 pandemic in the United States
title Effect of visual impairment on depression and anxiety during the COVID-19 pandemic in the United States
title_full Effect of visual impairment on depression and anxiety during the COVID-19 pandemic in the United States
title_fullStr Effect of visual impairment on depression and anxiety during the COVID-19 pandemic in the United States
title_full_unstemmed Effect of visual impairment on depression and anxiety during the COVID-19 pandemic in the United States
title_short Effect of visual impairment on depression and anxiety during the COVID-19 pandemic in the United States
title_sort effect of visual impairment on depression and anxiety during the covid-19 pandemic in the united states
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9712066/
https://www.ncbi.nlm.nih.gov/pubmed/36529268
http://dx.doi.org/10.1016/j.jcjo.2022.11.019
work_keys_str_mv AT sekimitsusayuri effectofvisualimpairmentondepressionandanxietyduringthecovid19pandemicintheunitedstates
AT shweikhyusrah effectofvisualimpairmentondepressionandanxietyduringthecovid19pandemicintheunitedstates
AT zebardastnazlee effectofvisualimpairmentondepressionandanxietyduringthecovid19pandemicintheunitedstates